Active, not recruitingPhase 2NCT02523040
Lenalidomide for Adult Histiocyte Disorders
Studying Erdheim-Chester disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Principal Investigator
- Eric Jacobsen, MD, M.DDana-Farber Cancer Institute
- Intervention
- Lenalidomide(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2026
Study locations (1)
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Collaborators
Celgene
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02523040 on ClinicalTrials.govOther trials for Erdheim-Chester disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07454343ECD-Score: a Study on Erdheim-Chester DiseaseMeyer Children's Hospital IRCCS
- RECRUITINGNCT05915208Histiocytic Disorder Follow-up StudyUniversity of Alabama at Birmingham
- RECRUITINGEARLY PHASE1NCT05093335In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PETMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT04079179Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic DisordersCarl Allen
- RECRUITINGNCT03990428Supportive Care Needs of Caregivers of People With Erdheim-Chester Disease and Other Histiocytic DiseasesMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT03329274Registry for Patients With Erdheim-Chester Disease and Other HistiocytosesMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT02285582International Rare Histiocytic Disorders Registry (IRHDR)The Hospital for Sick Children